Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP4C | P60510 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.86 |
| ▸ | MAP1B | P46821 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fostriecin SCHEMBL10738892 | 1.00 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL10738899 | 1.00 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL469219 | 1.00 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL10030539 | 1.00 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL5052 | 0.99 | PPP4C (0.98) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL31052709 | 0.93 | MAPT (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL21408783 | 0.93 | MAPT (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL29370092 | 0.93 | MAPT (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| SCHEMBL442237 | 0.92 | PPP4C (0.86) | PPP4CMAPTTDP1MAP1BMEN1 | |
| SCHEMBL444441 | 0.92 | PPP4C (0.86) | PPP4CMAPTTDP1MAP1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10019 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-12440479-B2 | Prevention or treatment of chronic organ injury | GEORG-AUGUST-UNIVERSITAET GOETTINGEN, STIFTUNG OEFFENTLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2025-10-14 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| EP-3966344-B1 | KINASE SCREENING ASSAYS | UNIV NEWCASTLE (GB) | 2025-06-25 | — | — | EP | claimed |
| WO-2025125890-A1 | PROTEIN PHOSPHATASE 2A (PPA2) ANTAGONISTS FOR DENGUE TREATMENT | CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL I.P.N. (MX) | 2025-06-19 | — | — | WO | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-20240218051-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | GENZYME CORPORATION | 2024-07-04 | — | — | US | claimed |
| WO-2024067670-A1 | ANTIBODY AND CONJUGATE | 苏州智核生物医药科技有限公司 | 2024-04-04 | — | — | WO | claimed |
| US-11879004-B2 | Modified binding polypeptides for optimized drug conjugation | GENZYME CORPORATION (US) | 2024-01-23 | — | — | US | claimed |
| WO-1999064054-A1 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5914242-A | ADMINISTERING FOSTRIECIN OR ANALOG TO PATIENT AFTER ONSET OF CARDIAC ISCHEMIA | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 1999-06-22 | — | — | US | claimed |
| WO-1998014606-A9 | METHOD FOR DIMINISHING MYOCARDIAL INFARCTION USING PROTEIN PHOSPHATASE INHIBITORS | — | 1998-08-13 | — | — | WO | claimed |
| WO-1998014606-A1 | METHOD FOR DIMINISHING MYOCARDIAL INFARCTION USING PROTEIN PHOSPHATASE INHIBITORS | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 1998-04-09 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0206490-B1 | ANTIBIOTIC CLATHRATES | WARNER-LAMBERT COMPANY (US) | 1990-03-14 | — | — | EP | claimed |
| US-4663316-A | Antibiotic clathrates and pharmaceutical compositions thereof | WARNER-LAMBERT COMPANY (US) | 1987-05-05 | — | — | US | claimed |
| EP-0206490-A2 | Antibiotic clathrates | WARNER-LAMBERT COMPANY (US) | 1986-12-30 | — | — | EP | claimed |
| EP-0128651-A2 | Pyranones and related compounds and methods for their production and use | WARNER-LAMBERT COMPANY (US) | 1984-12-19 | — | — | EP | claimed |